[1]袁英淇　闫润芝　范益民等.IFI 30、PD-L1在人脑胶质瘤中的表达及与病人预后的关系[J].中国临床神经外科杂志,2021,26(11):835-838.[doi:10.13798/j.issn.1009-153X.2021.11.006]
　YUAN Ying-qi,YAN Run-zhi,FAN Yi-min.Expression changes of IFI 30 and PD-L1 in human glioma tissues and their relationship with glioma patients’ prognoses[J].,2021,26(11):835-838.[doi:10.13798/j.issn.1009-153X.2021.11.006]
点击复制

IFI 30、PD-L1在人脑胶质瘤中的表达及与病人预后的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
26
期数:
2021年11期
页码:
835-838
栏目:
论著
出版日期:
2021-11-25

文章信息/Info

Title:
Expression changes of IFI 30 and PD-L1 in human glioma tissues and their relationship with glioma patients’ prognoses
文章编号:
1009-153X（2021）11-0841-04
作者:
袁英淇　闫润芝　范益民等
030001 太原，山西医科大学第一临床医学院神经外科（袁英淇）；030001 太原，山西医科大学第一医院神经外科（闫润芝、范益民）
Author(s):
YUAN Ying-qi;  YAN Run-zhi;  FAN Yi-min
1. Department of Neurosurgery, The First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China; 2. Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
脑胶质瘤; 预后; γ干扰素诱导蛋白30; 程序性死亡因子配体1; 基因表达
Keywords:
Glioma;  Interferon induced protein 30;  Programmed death-ligand 1;  Prognosis;  Gene expression
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2021.11.006
文献标志码:
A
摘要:
目的 探讨γ干扰素诱导蛋白30（IFI 30）、程序性死亡因子配体1（PD-L1）在人脑胶质瘤中的表达及与病人预后的关系。方法 选择2015年5月~2019年5月手术切除的103例人脑胶质瘤组织和瘤旁组织，采用免疫组织化学染色检测IFI 30、PD-L1表达情况。随访24个月，记录无进展生存期和总生存期。结果 胶质瘤组织IFI 30、PD-L1高表达率[分别为70.87%（73/103）、68.93%（71/103）]明显高于瘤旁组织[分别为19.42%（20/103）、21.36%（22/103）；P<0.001]。胶质瘤组织IFI 30表达水平与PD-L1表达水平呈明显正相关（r=0.583，P<0.05）。随访24个月，生存75例，死亡28例；多因素logistic回归分析显示，IFI 30高表达、PD-L1高表达是增加病人死亡风险的独立危险因素（P<0.05）。生存曲线分析显示，IFI 30高表达组2年累积生存率（64.52%）和2年累积无进展生存率（65.56%）均明显低于低表达组（分别为82.25%、89.45%；P<0.05）。PD-L1高表达组2年累积生存率（61.78%）和2年累积无进展生存率（60.14%）均明显低于低表达组（分别为88.52%、79.86%；P<0.05）。结论 人脑胶质瘤组织IFI 30、PD-L1呈高表达，与病人不良预后密切相关。
Abstract:
Objective To investigate the expression changes of interferon induced protein 30 (IFI 30) and programmed death-ligand 1 (PD-L1) in human glioma tissues and their relationship with glioma patients’ prognoses. Methods The expression levels of IFI 30 and PDL-1 were detected in the human glioma tissues and the tissues adjacent to glioma obtained from 103 glioma patients who underwent mirocurgery from May 2015 to may 2019 by immunohistochemical staining. All the patients were followed up for 2 years and the progress-free survival (PFS) and overall survival (OS) were recorded. Results The high expression rates of IFI 30 and PD-L1 in glioma tissues [70.87%(73/103) and 68.93%(71/103), respectively] were significantly higher than those in the tissues adjacent to glioma [19.42%(20/103) and 21.36%(22/103), respectively; P<0.001]. The expression level of IFI 30 was significantly correlated with the expression level of PD-L1 in glioma tissues (r=0.583; P<0.05). Of 103 glioma patients, 75 patients survived and 28 died at the last follow up. Multivariate logistic regression analysis showed that high expression of IFI 30 and high expression of PD-L1 were independent risk factors for poor prognoses of glioma patients (P<0.05). Survival curve analysis showed that the 2-year cumulative survival rate (64.52%) and 2-year cumulative progression-free survival (PFS) rate (65.56%) of the IFI 30 high expression group were significantly lower than those (82.25% and 89.45%, respectively) of the low expression group (P<0.05 ); the 2-year cumulative survival rate (61.78%) and 2-year cumulative progression-free survival rate (60.14%) of the PD-L1 high expression group were significantly lower than those (88.52%, 79.86%, respectively) of the low expression group (P<0.05). Conclusions IFI 30 and PD-L1 are up-regulated in human glioma which are closely related to the poor prognoses of the glioma patients.

参考文献/References:

[1] Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progres-sion [J]. Nature, 2019, 573(7775): 532-538.
[2] Tsutsumi S, Saeki H, Nakashima Y, et al. Programmeddeath-ligand 1 expression at tumor invasive front is associ-ated with epithelial-mesenchymal transition and poor prog-nosis in esophageal squamous cell carcinoma [J]. Cancer Sci, 2017, 108(6): 1119-1127.
[3] 陈三送，姚　林，王其福，等. γ-干扰素诱导的溶酶体硫醇还原酶在胶质瘤中的表达及其与胶质瘤化疗耐药关系[J]. 皖南医学院学报，2020，39（6）：18-21.
[4] Zhu C, Chen X, Guan G, et al. IFI30 is a novel immune-related target with predicting value of prognosis and treat-ment response in glioblastoma [J]. Onco Targets Ther, 2020,13: 1129-1143.
[5] 陈　杰. 病理诊断免疫组化手册[M]. 北京：中国协和医科大学出版社，2014. 77.
[6] 赵建辉，胡世颉，李　兵，等. 胶质瘤临床诊疗研究进展[J]. 中华神经外科疾病研究杂志，2017，16（4）：374-377.
[7] 田　浩，康晓艳，朱海波，等. PD-1/PD-L1 在小细胞肺癌中的临床研究进展[J]. 中国肿瘤临床，2019，46（1）：44-48.
[8] Rausch MP, Hastings KT. Diverse cellular and organismal functions of the lysosomal thiol reductase GILT [J]. MolImmunol, 2015, 68(2): 124-128.
[9] Liu X, Song C, Yang S, et al. IFI30 expression is an inde-pendent unfavourable prognostic factor in glioma [J]. J Cell Mol Med, 2020, 24(21): 12433-12443.
[10] 李巧转，李　娴. PD-L1在人胶质瘤中的表达及其对肿瘤内浸润性T细胞凋亡的影响[J]. 重庆医学，2018，47（1）：43-45.
[11] 白庆岭，胡长伟，彭营影，等. 脑胶质瘤预后影响因素分析[J]. 临床误诊误治，2018，31（7）：97-100.

相似文献/References:

[1]于　涛　黄正通　王振宇.椎管内脊膜囊肿的临床特征和治疗方法[J].中国临床神经外科杂志,2015,(11):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
　YU Tao,HUANG Zheng-tong,WANG Zhen-yu.Clinical features and treatment of intraspinal arachnoid cysts[J].,2015,(11):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
[2]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(11):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[3]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(11):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[4]周　量　刘　丛　张昌伟.早期栓塞术治疗动脉瘤性蛛网膜下腔出血的疗效[J].中国临床神经外科杂志,2016,(07):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
　ZHOU Liang,LIU Cong,ZHANG Chang-wei..Curative effect of early endovascular embolization on patients with ruptured intracranial aneurysms[J].,2016,(11):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
[5]陈吉钢　张丹枫　魏嘉良　邹　伟　侯立军.创伤性眶上裂综合征的治疗陈吉钢[J].中国临床神经外科杂志,2016,(04):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
　CHEN Ji-gang,ZHANG Dan-feng,WEI Jiang-liang,et al.Management of traumatic superior orbital fissure syndrome (report of 22 cases)[J].,2016,(11):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
[6]申彦杰　宋　健　成文平　程东亮.微血管减压术治疗面肌痉挛57例[J].中国临床神经外科杂志,2016,(04):238.[doi:10.13798/j.issn.1009-153X.2016.04.016]
[7]朱作磊 综述　罗良生 审校.动脉瘤性蛛网膜下腔出血的预后相关因素研究进展[J].中国临床神经外科杂志,2016,(03):183.[doi:10.13798/j.issn.1009-153X.2016.03.020]
[8]李玉龙　方兴根　李真保　吴德刚　赖年升　赵心同　徐善水　狄广福.血管内治疗颈内动脉床突旁破裂动脉瘤[J].中国临床神经外科杂志,2016,(02):79.[doi:10.13798/j.issn.1009-153X.2016.02.006]
　LI Yu-long,FANG Xing-gen,LI Zhen-bao,et al.Endovascular embolization of ruptured paraclinoid aneurysms (report of 26 cases)[J].,2016,(11):79.[doi:10.13798/j.issn.1009-153X.2016.02.006]
[9]皮水平　刘　杰　黄前樟.长期服用抗凝药物的老年颅脑损伤患者治疗体会[J].中国临床神经外科杂志,2016,(02):117.[doi:10.13798/j.issn.1009-153X.2016.02.022]
[10]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(11):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[11]周相军　朱娜娜　李　浩.血清TGF-β、VTN水平与成人脑胶质瘤病理分级及预后的关系[J].中国临床神经外科杂志,2019,(12):727.[doi:10.13798/j.issn.1009-153X.2019.12.003]
　ZHOU Xiang-jun,ZHU Na-na,LI Hao..Relationship of serum levels of TGF-β and VTN with pathological grade of tumors and prognosis in adult patients with cerebral gliomas[J].,2019,(11):727.[doi:10.13798/j.issn.1009-153X.2019.12.003]
[12]胡旭磊　何　涛　孙胜玉　邹有瑞　马　辉.氢质子磁共振波谱成像在脑胶质瘤诊断中的研究进展[J].中国临床神经外科杂志,2020,(07):485.[doi:10.13798/j.issn.1009-153X.2020.07.025]
[13]唐　宁　赵　群　喻坚柏.人脑胶质瘤P53、Bax蛋白表达变化及其与病人预后的关系[J].中国临床神经外科杂志,2020,(10):683.[doi:10.13798/j.issn.1009-153X.2020.10.008]
　TANG Ning,ZHAO Qun,YU Jian-bai..Changes of P53 and Bax protein expression in human glioma tissues and their relationship with patients’ prognosis[J].,2020,(11):683.[doi:10.13798/j.issn.1009-153X.2020.10.008]
[14]卓胜华　张金本　羊良旺　陈申波　张召腾　李争争　杨　堃.METTL21B在人脑胶质瘤中的表达与临床意义[J].中国临床神经外科杂志,2020,(10):692.[doi:10.13798/j.issn.1009-153X.2020.10.011]
　ZHUO Sheng-hua,ZHANG Jin-ben,YANG Liang-wang,et al.Expression and clinical significance of methyltransferase METTL21B in human brain gliomas[J].,2020,(11):692.[doi:10.13798/j.issn.1009-153X.2020.10.011]
[15]乔建新　刘熙鹏　段升强　刘　明　曹　兵.胶质瘤组织UCH37表达水平与病人预后的相关性[J].中国临床神经外科杂志,2021,26(06):426.[doi:10.13798/j.issn.1009-153X.2021.06.007]
　QIAO Jian-xin,LIU Xi-peng,DUAN Sheng-qiang,et al.Correlation between expression level of UCH37 in glioma tissues and prognoses of glioma patients[J].,2021,26(11):426.[doi:10.13798/j.issn.1009-153X.2021.06.007]
[16]王孝安　陈一楠　程传东　计　颖.Geminin表达水平与脑胶质瘤病人预后的关系[J].中国临床神经外科杂志,2021,26(08):600.[doi:10.13798/j.issn.1009-153X.2021.08.009]
　WANG Xiao-an,CHEN Yi-nan,CHENG Chuan-dong,et al.Relationship between Geminin expression and survival outcome of glioma patients[J].,2021,26(11):600.[doi:10.13798/j.issn.1009-153X.2021.08.009]
[17]胡　荣　赵　武　张亚森　李苑奇.lncRNA-FTX与脑胶质瘤病人预后的相关性分析[J].中国临床神经外科杂志,2021,26(09):679.[doi:10.13798/j.issn.1009-153X.2021.09.008]
　HU Rong,ZHAO Wu,ZHANG Ya-sen,et al.Correlation between lncRNA FTX level in glioma tissues and survival prognosis of patients with glioma[J].,2021,26(11):679.[doi:10.13798/j.issn.1009-153X.2021.09.008]
[18]孙玉书,王飞,王振飞,等.脑胶质瘤病人血浆miR-9-3p的变化及其与病人临床预后的关系[J].中国临床神经外科杂志,2022,27(08):653.[doi:10.13798/j.issn.1009-153X.2022.08.009]
　SUN Yu-shu,WANG Fei,WANG Zhen-fei,et al.Relationship between plasma level of miR-9-3p and survical pronosis of patients with glioma[J].,2022,27(11):653.[doi:10.13798/j.issn.1009-153X.2022.08.009]
[19]杜蓓,张民,张建飞,等.脑胶质瘤组织去泛素化酶USP9X表达水平与病人生存预后的关系[J].中国临床神经外科杂志,2023,28(12):712.[doi:10.13798/j.issn.1009-153X.2023.12.011]
　DU Bei,ZHANG Min,ZHANG Jian-fei,et al.Relationship between expression level of USP9X in glioma tissues and survival prognosis of patients with gliomas[J].,2023,28(11):712.[doi:10.13798/j.issn.1009-153X.2023.12.011]
[20]张娇,黄纯海,毛辉.KDELR2在胶质瘤中的表达及临床意义：基于组织芯片技术分析[J].中国临床神经外科杂志,2024,29(03):151.[doi:10.13798/j.issn.1009-153X.2024.03.006]
　ZHANG Jiao,HUANG Chun-hai,MAO Hui.Expression of KDELR2 in glioma tissues and its clinical significance: an analysis based on tissue microarray technology[J].,2024,29(11):151.[doi:10.13798/j.issn.1009-153X.2024.03.006]

更新日期/Last Update: 1900-01-01